基础医学与临床 ›› 2015, Vol. 35 ›› Issue (11): 1567-1571.
• 短篇综述 • 上一篇 下一篇
孙平风,傅芬
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
基金资助:
,
Received:
Revised:
Online:
Published:
摘要： 表皮生长因子受体III型突变体(EGFRvIII)作为最常见的表皮生长因子受体(EGFR)基因突变类型，只表达于恶性肿瘤，而不表达于正常组织中，是肿瘤特异性标志物，可作为卵巢癌靶向治疗的靶点。
关键词: 表皮生长因子受体, 表皮生长受体III型突变体, 卵巢癌, 靶向治疗
Abstract: The epidermal growth factor receptor variant III (EGFRvIII) also known as the most common mutant form of EGFR is a tumor-specific mutation, hasn’t yet been detected in normal tissues. It is regarded as a tumor-specific gene and offers a new way for targeted therapy of ovarian cancer.
Key words: epidermal growth factor receptor, epidermal growth factor receptor variant III, ovarian cancer, targeted treatment
中图分类号:
R73
孙平风 傅芬. 表皮生长因子受体Ⅲ型突变体在卵巢癌中检测及靶向治疗的研究进展[J]. 基础医学与临床, 2015, 35(11): 1567-1571.
0 / / 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2015/V35/I11/1567
